Innovent Biologics

elsewhere's corpus barely covers Innovent Biologics (信达生物) as a subject — there's no dedicated profile of the company in this material. The only substantive mention comes from a FreeS Fund (峰瑞资本) year-end piece by Li Feng, which notes that Innovent's October 2025 licensing deal with Takeda Pharmaceutical helped push Chinese innovative drug out-licensing volume past a cumulative US$100 billion — a milestone Li Feng calls "a very meaningful inflection point" . That framing tells you how the industry sees Innovent: one of the leading players in China's biotech out-licensing wave. Beyond that deal reference, elsewhere's corpus does not cover Innovent's founding, pipeline, or financials.